Overview

Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)

Status:
Terminated

Trial end date:
2019-10-30

Target enrollment:

Participant gender:

Summary

This research study is studying a drug as a possible treatment for heparin induced thrombocytopenia (HIT) or Heparin-induced Thrombocytopenia and Thrombosis (HITT). The drug involved in this study is apixaban.

Phase:

Phase 2

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborator:

Bristol-Myers Squibb

Treatments:

Apixaban
Calcium heparin
Heparin